TRIAL DETAIL

Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors

Drug:
Trial Name:
Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 04/01/2000
Age of Trial (yrs) 19.5
Treatment Phase:
First-line
Drug Category:
SDH-directed
Strategy:
Interfere with DNA replication
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CDR0000067710, SWOG-S9926
Sponsor:
SWOG, NCI
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Study Chair: Mark M. Zalupski, MD University of Michigan Cancer Center

This phase II trial is complete.This sarcoma trial included 19 GIST patients, the median time to disease progression was 2.3 months in patients with GISTs and 3.3 months in patients with other STSs (see the trial results link). The authors conclusions were: The data from the current study suggest that temozolomide is well tolerated but has only minimal efficacy and a limited role in the treatment of patients with STSs.

Trial Links

Trial Results

 

Drug Information

Temodar prescribing information
 
Temozolomide - Wikipedia
 
NCI - Temozolomide
 
U.S. National Library of Medicine - Drug Info
 

Trial Sites

Name
Address
City
State
Zip
Country